<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00301873</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00010125</org_study_id>
    <secondary_id>P50NS020023</secondary_id>
    <nct_id>NCT00301873</nct_id>
  </id_info>
  <brief_title>Zoledronate in Preventing Osteoporosis in Patients With Primary Malignant Glioma</brief_title>
  <official_title>Phase II Study of Zometa (Zoledronic Acid) to Prevent Osteoporosis in Patients With Brain Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Neurological Disorders and Stroke (NINDS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Zoledronate may prevent bone loss in patients with primary malignant glioma.

      PURPOSE: This phase II trial is studying how well zoledronate works in preventing
      osteoporosis in patients with primary malignant glioma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-labeled trial to determine the incidence of osteoporosis in brain tumor
      patients and effect of Zometa every three months. Zometa will be given at 4 mg intravenously
      over 15 minutes every 3 months for 1 year. The patients will undergo a baseline bone
      densitometry test that will be repeated at six months and one year. Information on the
      patient's tolerability of Zometa as well as any skeletal-related complications that happen
      will be collected. Data with respect to the dose and duration of glucocorticoids and
      anticonvulsants will be collected since both of these therapies have shown to directly affect
      bone density. Serial markers (N-telopeptide) of bone turn over will be collected at baseline
      and every 3 months prior to the infusion of Zometa. Karnofsky performance status will be
      monitored as a function of mobility.

      Accrual Goal 60 patients over a 18-month period, averaging 3-4 new enrollees per month.
      Thirty-five patients to reach the 6-month assessment.

      OBJECTIVES:

        -  To determine the bone mineral density of the patients at baseline and any changes over
           12 months while receiving Zometa every 3 months.

        -  To determine the incidence of skeletal-related complications in this cohort of brain
           tumor patients.

        -  To determine the safety and tolerability of Zometa in brain tumor patients.

        -  To determine the effects of glucocorticoids and anticonvulsants on bone density.

      Response Criteria The primary efficacy endpoint will be the patient's bone densitometry, and
      how it changes over the course of one year of Zometa therapy. The bone densitometry after 6
      months and 12 months of Zometa will be compared to the baseline. The secondary efficacy
      variable will be the prevention of skeletal-related events (compression fracture, any
      fracture requiring surgery) which given the heterogeneity of the patient population will be a
      qualitative variable. Date with respect to the dose and duration of glucocorticoids and
      anticonvulsants will be collected since both of these therapies have shown to directly affect
      bone density. Serial markers (N-telopeptide) of bone turn over will be collected.

      Outcome assessment The patient's bone densitometry will be determined by Dexa-scan at the
      baseline, after six months of Zometa and after one year of Zometa. The bone density (Dexa-
      scan) will be reviewed by the outside radiologist or Duke radiology in conjunction with the
      primary investigator. A decrease of &gt; -0.5 on the T-score will be coded as a treatment
      failure and patients will be discontinued from the study and referred to Endocrinology or
      Orthopedic Surgery for best clinical management. In addition, any skeletal-related event
      (fractures) will be coded as a treatment failure. The patient population will be
      heterogeneous in terms of their functional capacity, exercise capacity, anticonvulsant and
      glucocorticoid dos
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2006</start_date>
  <completion_date type="Actual">September 2012</completion_date>
  <primary_completion_date type="Actual">February 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent of Patients With Change in Combined Bone Mass Density T-score &lt;= -0.5.</measure>
    <time_frame>6 and 12 months</time_frame>
    <description>Percent of patients who failed treatment as defined by a decrease of 0.5 or more from baseline in the combined T-score as measured by Dexa-scan. The patient's bone densitometry was determined by Dexa-scan at baseline, after 6 months of Zometa and after 1 year of Zometa. The t-score, which is a comparison of a person's bone density with that of a healthy 30-year-old of the same sex, was generated by Dexa-scan for the spine and femur. The combined T-score is the minimum of the T-score for the spine and femur. A lower t-score implies a lower BMD.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Skeletal-related Complications</measure>
    <time_frame>1 year</time_frame>
    <description>Number of patients who experience skeletal-related complications during the administration of Zoledronate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in Bone Mass Density (BMD)</measure>
    <time_frame>6 &amp; 12 months</time_frame>
    <description>Mean change in the combined t-score was measured by Dexa-scan. The patients bone density was determined by Dexa-scan at baseline, after 6 months Zometa and after 12 months of Zometa. The t-score, which is a comparison of a person's bone density with that of a healthy 30-year old of the same sex, was generated by Dexa-scan for the spine and femur. A lower t-score implies a lower BMD. The combined t-score is the minimum of the t-score for the spine and that for the femur. BMD change from baseline at 6 and 12 months in the combined t-score was defined as the follow-up combined t-score minus the baseline combined t-score.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Brain Tumors</condition>
  <condition>Osteoporosis</condition>
  <condition>Central Nervous System(CNS)Malignancies</condition>
  <arm_group>
    <arm_group_label>IV Zometa</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Zometa will be given at 4 mg intravenously over 15 minutes every 3 months for 1 year.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IV Zometa</intervention_name>
    <description>Zometa will be given at 4 mg intravenously over 15 minutes every 3 months for 1 year.</description>
    <arm_group_label>IV Zometa</arm_group_label>
    <other_name>zolondronic acid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients must have histologically confirmed diagnosis of a primary brain tumor.

          2. Patients must be on Depakote ( Valproic Acid) or one of the following enzyme inducing
             anticonvulsants (EIAC) therapies. Phenobarbital, Dilantin, Trileptal, Tegretol and/or
             on more than physiologic replacement steroid therapy (Dexamethasone &gt;0.75 mg/d,
             prednisone &gt;5 mg/d or hydrocortisone &gt;20 mg/d).

          3. Age &gt; 18 years.

          4. Karnofsky performance score &gt; 60%

          5. Adequate renal and liver function as demonstrated by laboratory values performed
             within 14 days, inclusive, prior to the administration of Zometa, except for the
             creatinine, which will be within 72 hs of Zometa administration:

               -  Serum creatinine &lt; 2.0 mg/dl and calculated creatinine clearance of &gt;60 mL/min

               -  Total serum bilirubin &lt; 1.5 times upper limit of laboratory normal

               -  Serum glutamoc-oxaloacetic transaminase (SGOT) and serum glutamic pyruvic
                  transaminase (SGPT) &lt; 2.5 times upper limit of laboratory normal

               -  Alkaline phosphatase of &lt;2 times upper limit of laboratory normal

          6. Patients must have recovered from any effects of major surgery.

          7. Patients must have a life expectancy of greater than 12 weeks.

          8. Patients or legal guardian must give written, informed consent.

        Exclusion Criteria:

          1. Patients who are poor medical risks because of non-malignant systemic disease as well
             as those with acute infection treated with intravenous antibiotics.

          2. Previous or concurrent malignancies at other sites with the exception of surgically
             cured carcinoma in-situ of the cervix and basal or squamous cell carcinoma of the
             skin.

          3. Known HIV positivity or AIDS-related illness.

          4. Pregnant or nursing women.

          5. Women of childbearing potential who are not using an effective method of
             contraception. Women of childbearing potential must have a negative serum pregnancy
             test 72hours prior to administration of study and be practicing medically approved
             contraceptive precautions.

          6. Men who are not advised to use and effective method of contraception.

          7. Patients previously diagnosed with osteoporosis requiring oral bisphosphonates.

          8. Known hypersensitivity to Zometa® (zoledronic acid) or other bisphosphonates

          9. Current active dental problems including infection of the teeth or jawbone
             osteonecrosis of the jaw (ONJ), of exposed bone in the mouth, or of slow healing after
             dental procedures.

         10. Recent (within 6 weeks) or planned dental or jaw surgery (e.g.. extraction, implants).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James J. Vredenburgh, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Duke Comprehensive Cancer Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 9, 2006</study_first_submitted>
  <study_first_submitted_qc>March 9, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 13, 2006</study_first_posted>
  <results_first_submitted>October 15, 2012</results_first_submitted>
  <results_first_submitted_qc>December 10, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 16, 2013</results_first_posted>
  <last_update_submitted>February 13, 2013</last_update_submitted>
  <last_update_submitted_qc>February 13, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 18, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>osteoporosis</keyword>
  <keyword>adult anaplastic astrocytoma</keyword>
  <keyword>adult giant cell glioblastoma</keyword>
  <keyword>adult anaplastic oligodendroglioma</keyword>
  <keyword>adult gliosarcoma</keyword>
  <keyword>adult mixed glioma</keyword>
  <keyword>recurrent adult brain tumor</keyword>
  <keyword>adult glioblastoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zoledronic acid</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients were accrued between February 2006 and January 2008 within the clinic at Duke Comprehensive Cancer Center.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>IV Zometa</title>
          <description>Zometa will be given at 4 mg intravenously over 15 minutes every 3 months for 1 year.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="59"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="59"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>IV Zometa</title>
          <description>Zometa will be given at 4 mg intravenously over 15 minutes every 3 months for 1 year.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="59"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54.7" spread="9.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Anticonvulsant use</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>no</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Steroid use</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>no</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent of Patients With Change in Combined Bone Mass Density T-score &lt;= -0.5.</title>
        <description>Percent of patients who failed treatment as defined by a decrease of 0.5 or more from baseline in the combined T-score as measured by Dexa-scan. The patient's bone densitometry was determined by Dexa-scan at baseline, after 6 months of Zometa and after 1 year of Zometa. The t-score, which is a comparison of a person’s bone density with that of a healthy 30-year-old of the same sex, was generated by Dexa-scan for the spine and femur. The combined T-score is the minimum of the T-score for the spine and femur. A lower t-score implies a lower BMD.</description>
        <time_frame>6 and 12 months</time_frame>
        <population>59 patients were accrued; however only 27 had a follow-up assessment at 6 months and 19 at 12 months.</population>
        <group_list>
          <group group_id="O1">
            <title>IV Zometa</title>
            <description>Zometa will be given at 4 mg intravenously over 15 minutes every 3 months for 1 year.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Patients With Change in Combined Bone Mass Density T-score &lt;= -0.5.</title>
          <description>Percent of patients who failed treatment as defined by a decrease of 0.5 or more from baseline in the combined T-score as measured by Dexa-scan. The patient's bone densitometry was determined by Dexa-scan at baseline, after 6 months of Zometa and after 1 year of Zometa. The t-score, which is a comparison of a person’s bone density with that of a healthy 30-year-old of the same sex, was generated by Dexa-scan for the spine and femur. The combined T-score is the minimum of the T-score for the spine and femur. A lower t-score implies a lower BMD.</description>
          <population>59 patients were accrued; however only 27 had a follow-up assessment at 6 months and 19 at 12 months.</population>
          <units>percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>At 6 months (n=27)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At 12 months (n=19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Skeletal-related Complications</title>
        <description>Number of patients who experience skeletal-related complications during the administration of Zoledronate.</description>
        <time_frame>1 year</time_frame>
        <population>All patients.</population>
        <group_list>
          <group group_id="O1">
            <title>IV Zometa</title>
            <description>Zometa will be given at 4 mg intravenously over 15 minutes every 3 months for 1 year.</description>
          </group>
        </group_list>
        <measure>
          <title>Skeletal-related Complications</title>
          <description>Number of patients who experience skeletal-related complications during the administration of Zoledronate.</description>
          <population>All patients.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change in Bone Mass Density (BMD)</title>
        <description>Mean change in the combined t-score was measured by Dexa-scan. The patients bone density was determined by Dexa-scan at baseline, after 6 months Zometa and after 12 months of Zometa. The t-score, which is a comparison of a person’s bone density with that of a healthy 30-year old of the same sex, was generated by Dexa-scan for the spine and femur. A lower t-score implies a lower BMD. The combined t-score is the minimum of the t-score for the spine and that for the femur. BMD change from baseline at 6 and 12 months in the combined t-score was defined as the follow-up combined t-score minus the baseline combined t-score.</description>
        <time_frame>6 &amp; 12 months</time_frame>
        <population>59 patients were accrued to the study; however follow-up at 6 months was available from 27 patients and at 12 months data was available from 19 patients.</population>
        <group_list>
          <group group_id="O1">
            <title>IV Zometa</title>
            <description>Zometa will be given at 4 mg intravenously over 15 minutes every 3 months for 1 year.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Bone Mass Density (BMD)</title>
          <description>Mean change in the combined t-score was measured by Dexa-scan. The patients bone density was determined by Dexa-scan at baseline, after 6 months Zometa and after 12 months of Zometa. The t-score, which is a comparison of a person’s bone density with that of a healthy 30-year old of the same sex, was generated by Dexa-scan for the spine and femur. A lower t-score implies a lower BMD. The combined t-score is the minimum of the t-score for the spine and that for the femur. BMD change from baseline at 6 and 12 months in the combined t-score was defined as the follow-up combined t-score minus the baseline combined t-score.</description>
          <population>59 patients were accrued to the study; however follow-up at 6 months was available from 27 patients and at 12 months data was available from 19 patients.</population>
          <units>T score units</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change in combined BMD at 6 months (n=27)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".01" spread=".21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in combined BMD at 12 months (n=19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-.06" spread=".31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>59 patients were accrued to the study. The 27 patients with follow-up at 6 months are included in an analysis to assess the association between baseline steroid use and bone mass density at 6 months using linear regression.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.2212</p_value>
            <p_value_desc>The p-value is a test of whether the slope of the regression line is non-zero.</p_value_desc>
            <method>Regression, Linear</method>
            <method_desc>The linear regression assesses the relationship between baseline baseline steroid use and BMD change at 6 months (outcome).</method_desc>
            <param_type>Slope</param_type>
            <param_value>-.107</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>.0855</dispersion_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>59 patients were accrued to the study. The 27 patients with follow-up at 6 months are included in an analysis to assess the association between baseline anticonvulsant use and bone mass density at 6 months using linear regression</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.0413</p_value>
            <p_value_desc>this p-value is at test of whether the slope of the regression line is non-zero.</p_value_desc>
            <method>Regression, Linear</method>
            <method_desc>The linear regression assesses the relationship between anticonvulsant use and BMD change at 6 months (outcome).</method_desc>
            <param_type>Slope</param_type>
            <param_value>.2357</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>.1091</dispersion_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>59 patients were accrued to the study. The 19 patients with follow-up at 12 months are included in an analysis to assess the association between baseline steroid use and bone mass density at 12 months using linear regression</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.0418</p_value>
            <p_value_desc>this p-value is at test of whether the slope of the regression line is non-zero.</p_value_desc>
            <method>Regression, Linear</method>
            <method_desc>The linear regression assesses the relationship between baseline steroid use and BMD change at 12 months (outcome).</method_desc>
            <param_type>Slope</param_type>
            <param_value>-.232</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>.1029</dispersion_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>59 patients were accrued to the study. The 19 patients with follow-up at 12 months are included in an analysis to assess the association between baseline anti-convulsant use and bone mass density at 12 months using linear regression</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.1026</p_value>
            <p_value_desc>the p-value is a test of whether the slope ofl the regression line is non-zero.</p_value_desc>
            <method>Regression, Linear</method>
            <method_desc>The linear regression assesses the relationship between anticonvulsant use and BMD change at 12 months.</method_desc>
            <param_type>Slope</param_type>
            <param_value>.2123</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>.1209</dispersion_value>
            <ci_percent>95</ci_percent>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>All Adverse Events regardless of grade over a period of 1 year</time_frame>
      <desc>Common Terminology for Adverse Events (CTCAE)3.0 used for collecting adverse events (AEs). Converted to 4.0 for this report. Serious Adverse Events(SAE): of the 16 pts affected by an SAE only, 3 were possibly, probably, or definitely related to Zometa. AEs: Of the 27 pts affected by an AE 12 were possibly, probably, or definitely related to Zometa.</desc>
      <group_list>
        <group group_id="E1">
          <title>IV Zometa</title>
          <description>Zometa will be given at 4 mg intravenously over 15 minutes every 3 months for 1 year.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>fever</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>infections and infestations-other</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Vascular access complication</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Generalized muscle weakness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Intracranial hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Peripheral motor neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Facial nerve disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>seizure</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Depressed level of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin ulceration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>phlebitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>thrombo embolic event</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>blurred vision</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>constipation</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>fatigue</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>fever</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>anorexia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Generalized muscle weakness</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>ataxia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>cognitive disturbance</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>dizziness</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>memory impairment</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Peripheral motor neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>seizure</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Depressed level of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>dysphasia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>insomnia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>confusion</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>mood alteration</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>urinary incontinence</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>erectile dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>rash maculo-papular</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Limitations include early pt termination leading to small numbers of subjects analyzed (eg no BMD study at 6 and/or 12 mos)secondary to the poor overall survival (eg median survival 3-9 mos)associated with recurrent glioblastoma multiforme(GBM) pts.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Mary Lou Affronti, RN, MSN, ANP, MHSc Senior Investigator</name_or_title>
      <organization>Duke Comprehensive Cancer Center</organization>
      <phone>919-684-6239</phone>
      <email>mary.affronti@duke.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

